The majority of patients with reduced LV function received a sufficient pharmacological heart failure treatment consisting of ACE inhibitor or AT blocker (87.3%), beta-blocker (87.3%), mineralocorticoid receptor antagonists (45.5%) and diuretics (92.7%). Here, NR3C2 is linked to heart failure.